3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Lung Neoplasms
1
Genital Neoplasms, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Advanced Solid Tumors
1
Interventions
Carboplatin
30
Cisplatin
23
pembrolizumab
22
Paclitaxel
21
Pemetrexed
20
Gemcitabine
10
osimertinib
9
durvalumab
9
Nivolumab
9
130-nm albumin-bound paclitaxel
8
Sunitinib
7
Sorafenib
7
Fluorouracil
7
Everolimus
7
Docetaxel
7
Axitinib
7
Cetuximab
6
epothilone B
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
volociximab
4
trebananib
4
reolysin
4
catumaxomab
4
cabozantinib
4
atezolizumab
4
Radiotherapy
4
Ipilimumab
4
vosaroxin
3
liposomal doxorubicin
3
lenvatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma
×
E-3810
×
Clear all
NCT04151563
2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2
Withdrawn